The Week in Review: February 23 – March 2, 2018

Friday, March 2, 2018 News Recap: Canada: Shifting from concern to crisis: 1 in 4 Canadians may be affected by liver disease. Recent indicators gathered by the Canadian Liver Foundation (CLF) show that an increased prevalence of liver diseases including non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B & C, and liver cancer are why in just ten years, the statistic that was once 1 in 10, is now 1 in 4. Ontario Expands Patient Acce...

Alpha Fetoprotein Testing May Detect Liver Cancer Sooner

Researchers from the UT Southwestern Simmons Cancer Center have conducted a study saying that ultrasound imaging when used in combination with blood testing for alpha fetoprotein could help to improve the detection of early stage liver cancer by 40%, as published in the journal Gastroenterology. Liver cancer screening guidelines vary, some calling for imaging alone and other calling for both blood tests along with imaging. Screening of patients with chron

The Week in Review: January 26 – February 2, 2018

Friday, February 2, 2018 News Recap: From the Uh-Oh Department: HCV Can Reactivate with Treatment of Non-hepatic Cancer. Hepatitis C virus (HCV) reactivation occurred in approximately 1 out of 5 patients treated for non-hepatic cancer, posing renewed risk for hepatic injury and possibly complicating the cancer treatment. Compensation Update: Compensation – New Update for 86-90 Late Claims. If you or a family member received a blood transfusion o...

Child-Pugh B, C scores predict failure in liver cancer surveillance

This article is about what happens when people with cirrhosis are not part of a screening program for liver cancer. Child-Pugh B and C, and elevated alpha-fetoprotein, at diagnosis of hepatocellular carcinoma corresponded with a diagnosis outside Milan criteria and surveillance failure during a surveillance program of patients with cirrhosis. “HCC surveillance in cirrhotic patients aims to detect tumors in the initial stages of the disease to offer tre

Now That We Have a Cure for Hepatitis C, What Are the Next Treatment Challenges?

Within the next few years, several pipeline hepatitis C (HCV) drugs are expected to be approved in the United States, ensuring that even the most difficult-to-treat patients will soon be able to be cured, according to experts interviewed at The Liver Meeting in Boston. "Very few patients are being warehoused because there are only a few very niche special populations left," noted Robert Brown, M.D., M.P.H., Gladys and Roland Harriman Professor of Medicine